Literature DB >> 1858036

Relation between p53 overexpression and established prognostic factors in breast cancer.

A M Davidoff1, J E Herndon, N S Glover, B J Kerns, J C Pence, J D Iglehart, J R Marks.   

Abstract

The nuclear phosphoprotein p53 is expressed in all normal cells and appears to function in cell cycle regulation. Abnormally high levels of the protein are found in many different types of cancer. In breast carcinoma overexpression of p53 is associated with point mutations within highly conserved regions of the p53 gene. These altered genes encode stable p53 proteins that can be detected by standard immunohistochemical techniques unable to detect rapidly degraded wild-type protein. The level of p53 expression in 184 primary breast cancer specimens was assessed by immunohistochemical analysis and related to the following established prognostic factors for breast cancer: age, stage, metastatic involvement, concentration of estrogen and progesterone receptors, proliferative index, and HER-2/neu overexpression. Fifty (27%) of these primary breast cancer specimens had widespread overexpression of p53. Highly significant associations were found between p53 overexpression and late stage, metastatic spread, and low concentration of progesterone receptors. The presence of elevated levels of mutant p53 may itself be a prognostic factor in human breast cancer and activation of this oncogene may be important in the ability of a tumor to metastasize.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858036

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  31 in total

1.  Immunohistochemical Detection of p53 and c-erbB-2 Proteins: Prognostic Significance in Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

2.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

3.  MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.

Authors:  Lenora W M Loo; Chong Gao; Yurii B Shvetsov; Danielle R Okoro; Brenda Y Hernandez; Jill Bargonetti
Journal:  Breast Cancer Res Treat       Date:  2018-11-23       Impact factor: 4.872

4.  Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.

Authors:  M Noguchi
Journal:  Ann Surg       Date:  1995-04       Impact factor: 12.969

5.  Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer.

Authors:  Hong Suk Song; Young Rok Do; Sun Hee Kang; Ki Yong Jeong; Yu Sa Kim
Journal:  Cancer Res Treat       Date:  2006-12-31       Impact factor: 4.679

6.  p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.

Authors:  H Moch; G Sauter; D Moore; M J Mihatsch; F Gudat; F Waldman
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.

Authors:  A M Davidoff; J D Iglehart; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Prognostic significance of p53 gene alterations in node-negative breast cancer.

Authors:  R M Elledge; S A Fuqua; G M Clark; P Pujol; D C Allred; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.

Authors:  R A Jensen; D L Page; J T Holt
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

10.  Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.

Authors:  W Domagala; B Harezga; A Szadowska; M Markiewski; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.